Drug · CHEMBL84
TOPOTECAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TOPOTECAN. Drugs and targets, record CHEMBL84. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL84
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Ff-10850 (liposomal topotecan), Hycamptamine, Hycamptin, NSC-609699, NSC-641007, Nogitecan, SK&F-104864, SKF-104864, Topotecane
- ChEMBL
- Open Targets' highest stage
- Approval, for 6 of its 87 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP1 | DNA topoisomerase 1 | DNA topoisomerase I inhibitor | INHIBITOR | https://conductscience.org/library/genes/7150 |
Source ChEMBL
Diseases87
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 87Source Open Targets
See all 87 diseasesTrials288
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02481830 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | Phase 3 | 569 | 2020-01-09 | topotecan | Its name | ClinicalTrials.gov |
| NCT00064077 | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | Phase 3 | 513 | 2018-08-28 | topotecan | Its name | ClinicalTrials.gov |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | Phase 3 | 509 | 2026-01-05 | topotecan | Its name | ClinicalTrials.gov |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | Phase 3 | 502 | 2024-08-09 | topotecan | Its name | ClinicalTrials.gov |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | Phase 3 | 491 | 2023-10-17 | topotecan | Its name | ClinicalTrials.gov |
| NCT00390806 | Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer | Phase 3 | 472 | 2014-01-20 | topotecan | Its name | ClinicalTrials.gov |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression | Phase 3 | 453 | 2024-08-01 | topotecan | Its name | ClinicalTrials.gov |
| NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | Phase 3 | 442 | 2020-03-05 | topotecan | Its name | ClinicalTrials.gov |
| NCT00065182 | Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer | Phase 2 | 399 | 2019-06-24 | topotecan | Its name | ClinicalTrials.gov |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | Phase 3 | 361 | 2015-02-25 | topotecan | Its name | ClinicalTrials.gov |
1 to 10 of 288
See all 288 trialsComparisons in its trials57
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group A vs Group B: deaths from any cause | 251 of 284 | 256 of 285 | 569 | NCT02481830 | Trial comparisons |
| Group A vs Group B: serious adverse events | 183 of 282 | 171 of 265 | 547 | NCT02481830 | Trial comparisons |
| Tarlatamab 1 mg to 10 mg Q2W vs Standard of Care (SOC): deaths from any cause | 111 of 254 | 152 of 255 | 509 | NCT05740566 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: deaths from any cause | 123 of 253 | 140 of 249 | 502 | NCT04697628 | Trial comparisons |
| Tarlatamab 1 mg to 10 mg Q2W vs Standard of Care (SOC): serious adverse events | 129 of 252 | 125 of 244 | 496 | NCT05740566 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 246 of 250 | 237 of 239 | 489 | NCT04697628 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: serious adverse events | 82 of 250 | 94 of 239 | 489 | NCT04697628 | Trial comparisons |
| Chemoradiation: Topotecan Plus WBRT vs Radiation: WBRT Alone: Number of Participants Who Died or Progressed | 179 of 235 | 161 of 233 | 468 | NCT00390806 | Trial comparisons |
| Chemoradiation: Topotecan Plus WBRT vs Radiation: WBRT Alone: serious adverse events | 96 of 235 | 43 of 233 | 468 | NCT00390806 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: deaths from any cause | 162 of 227 | 177 of 226 | 453 | NCT04209855 | Trial comparisons |
1 to 10 of 57
See all 57 comparisons in its trialsPapers from its trials134
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Verbal Fluency | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL84
GET https://conductscience.org/api/drugs/v1/CHEMBL84/diseases?page=2